Deal Watch: Amgen Takes Center Stage With Trio Of Transactions
Executive Summary
The big biotech enters a collaboration in cancer immunotherapy and inflammation with Xencor, acquires Dutch biotech Dezima, and licenses a c-MET inhibitor to NantWorks. Also, Sun Pharma steps in to buy InSite Vision, which had been targeted by QLT.
You may also be interested in...
Keeping Track: Venclexta Approved; Opdivo, Atezolizumab Seek Additional Indications
The latest drug development news and highlights from our FDA Performance Tracker.
Deal Watch: GSK Accelerates TCR Collaboration With Adaptimmune
Merger combines troubled Avalanche's resources with Annapurna's brimming pipeline. Janssen sells its BetaLogic stem-cell IP to partner ViaCyte to hasten development of a stem cell therapeutic for diabetes.
Biden’s Cancer Initiative May Intensify Industry, Government Collaboration
Drug companies and NIH embrace Vice President’s call for moonshot to cure cancer; Amgen and Celgene join separate coalition to test 60 molecules in combination Phase II studies.